NEW YORK--(BUSINESS WIRE)--Edgemont Partners (“Edgemont”), a premier healthcare investment bank and a leading M&A and capital raising advisor exclusively serving healthcare companies, announced that it acted as a financial advisor in the investment in Prescient Healthcare Group (“Prescient” or “the Company”) by Bridgepoint Development Capital (“Bridgepoint”). Prescient, a leading product strategy consultancy to the global biopharmaceutical industry, was a portfolio company of Baird Capital. The terms of the transaction, which closed on January 19, 2021, were not disclosed. Edgemont’s deal team included David Blume, Managing Director; Andrew Karlin, Director; Daniel Smallegan, Associate; and Analysts, Erick Pacher and Kabir Thakral.
Founded in 2007, Prescient is headquartered in London, with offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. Prescient partners with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations.
The recapitalization was led by an investment from Bridgepoint, a London-based private equity firm focused on acquiring middle-market businesses valued up to €1 billion. The transaction provided a full exit for Baird Capital, who made their initial investment in 2017. As part of the transaction, Baird Capital reinvested in Prescient as a minority shareholder alongside Bridgepoint.
Prescient’s partnership with Bridgepoint is Edgemont’s twenty-first pharmaceutical services transaction in the last three years. Other recent transactions include the recapitalization of PHASTAR by Charterhouse Capital Partners, the recapitalization of NAMSA by ArchiMed and the merger of Pharmerit with Open Health.
About Prescient Healthcare Group
Prescient is a pharma services firm specializing in dynamic decision support and product and portfolio strategy. We partner with our clients to turn science into value by helping them understand the potential of their molecules, shaping their strategic plans and allowing their decision making to be the biggest differentiating factor in the success of their products. When companies partner with Prescient, the molecules in their hands have a greater potential for success than the same science in the hands of their competitors.
Founded in 2007, Prescient is a global firm with six offices across three continents. Our team of more than 250 experts partners with 23 of the top 25 biopharmaceutical companies, the fastest-growing mid-caps and cutting-edge emerging biotechs, including some of the biggest and most innovative brands. More than 80% of our employees hold advanced life sciences degrees, and our teams deliver an impressive depth of therapeutic, clinical and commercial expertise. For more information, please visit www.PrescientHG.com.
Bridgepoint is an international alternative asset fund management group, with €26 billion assets under management and over €39 billion of capital raised to date. It typically focuses on acquiring well-managed companies in attractive sectors helping companies and management teams by investing in expansion, operational transformation or via consolidating acquisitions. It focuses on making investments in six core sectors: Business Services, Consumer, Financial Services, Healthcare, MedTech & Pharma, Manufacturing & Industrials and Digital, Technology & Media.
About Edgemont Partners
Now in its 20th year, Edgemont ranks among the most active and best-performing independent healthcare M&A and financial advisors in the U.S. We focus solely on providing expert strategic advice and transaction execution to healthcare and life sciences companies, bringing a steadfast commitment to our clients, driven always to prioritize their best interests. Edgemont’s principals have executed 170+ transactions with an aggregate value of $65 billion+.
Investment banking services are provided by Edgemont Capital Partners, LP, a registered broker-dealer and member of FINRA and SIPC.